Riding On Humira Sales, Abbott Aims For Dominance In Lipid Management Market
This article was originally published in The Pink Sheet Daily
Product launches and Humira label expansions will compensate for Depakote generics entering the market in July, CEO White says.
You may also be interested in...
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.
Valproic acid delayed release capsules gain tentative clearance for manic episodes associated with bipolar disorder and multiple seizures, including epilepsy.
Solvay will provide sales support in the U.S. in addition to funding development and promotions for the Niaspan/simvastatin combination.